As the market for epilepsy drugs emerges from the first patent cliff that eroded much of its value over 2008–09, Datamonitor Healthcare has been evaluating its prospects over the coming years. The value of the epilepsy market will undergo steady growth in the US and Japan, but – despite a spate of recent launches – in the five major EU markets it is likely to remain flat.
The US is the largest market for epilepsy drugs, owing to its large diagnosed patient population and the high prices...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?